HIGHLIGHTS
- who: Michaela C. Barbier and collaborators from the Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland, Epidemiology have published the paper: Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer, in the Journal: PLOS ONE of October/24,/2022
- what: The aim of this analysis was to investigate the cost-effectiveness of all current systemic first-line (1L) treatments for newly diagnosed mHSPC considering most up-to-date randomized controlled trial (RCT) data including the recent TITAN survival follow-up data . The model investigated the impact . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.